Inhibitors of intestinal barrier dysfunction

Pediatric and Adolescent Medicine

Volumn 12, Issue , 2008, Pages 157-171

  Paterson, Blake M ^a   Turner, Jerrold R ^b  

^a Alba Therapeutics Corporation   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953844415     PISSN: 10175989     EISSN: 16623886     Source Type: Book Series    
DOI: 10.1159/000129014     Document Type: Review

References (65)

1. Bjarnason I, Takeuchi K, Bjarnason A, Adler SN, Teahon K: The G. U. T. of gut. Scand J Gastroenterol 2004;39:807-815.
2. Clayburgh DR, Shen L, Turner JR: A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004;84:282-291. (Pubitemid 41656483)
3. Arrieta MC, Bistritz L, Meddings JB: Alterations in intestinal permeability. Gut 2006;55:1512-1520. (Pubitemid 44476799)
4. Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P: Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 2005;11:667-673. (Pubitemid 40961081)
5. Stevenson BR: Understanding tight junction clinical physiology at the molecular level. J Clin Invest 1999;104:3-4. (Pubitemid 29534338)
6. Berglund JJ, Riegler M, Zolotarevsky Y, Wenzl E, Turner JR: Regulation of human jejunal transmucosal resistance and MLC phosphorylation by Na (+) - glucose cotransport. Am J Physiol Gastrointest Liver Physiol 2001;281:G1487-G1493.
7. Sander GR, Cummins AG, Henshall T, Powell BC: Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett 2005;579:4851-4855. (Pubitemid 41218674)
8. Fukudo S: Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. JGastroenterol 2007;42(suppl 17):48-51. (Pubitemid 46140364)
9. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A: Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003;171:6164-6172. (Pubitemid 37467239)
10. Madara JL, Pappenheimer JR: Structural basis for physiological regulation of paracellular pathways in intestinal epithelia. JMembr Biol 1987;100:149-164. (Pubitemid 18004072)
11. Pappenheimer JR, Reiss KZ: Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J Membr Biol 1987;100:123-136. (Pubitemid 18004070)
12. Turner JR: Show me the pathway! Regulation of paracellular permeability by Na (+)-glucose cotransport. Adv Drug Deliv Rev 2000;41:265-281. (Pubitemid 30347378)
13. Turner JR: 'Putting the squeeze' on the tight junction: understanding cytoskeletal regulation. Semin Cell Dev Biol 2000;11:301-308. (Pubitemid 32066137)
14. Sadowski DC, Meddings JB: Luminal nutrients alter tight-junction permeability in the rat jejunum: an in vivo perfusion model. Can J Physiol Pharmacol 1993;71:835-839. (Pubitemid 24053562)
15. Meddings JB, Westergaard H: Intestinal glucose transport using perfused rat jejunum in vivo: model analysis and derivation of corrected kinetic constants. Clin Sci (Lond) 1989;76:403-413. (Pubitemid 19104294)
16. Turner JR, Cohen DE, Mrsny RJ, Madara JL: Noninvasive in vivo analysis of human small intestinal paracellular absorption: regulation by Na+-glucose cotransport. Dig Dis Sci 2000;45:2122-2126. (Pubitemid 32060380)
17. Clayburgh DR, Musch MW, Leitges M, Fu YX, Turner JR: Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest 2006;116:2682-2694. (Pubitemid 44511632)
18. Lee A, White N, van der Walle CF: The intestinal zonula occludens toxin (ZOT) receptor recognises non-native ZOT conformers and localises to the intercellular contacts. FEBS Lett 2003;555:638-642. (Pubitemid 37532623)
19. Fasano A: Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann NY Acad Sci 2000;915:214-222. (Pubitemid 32059382)
20. Salama NN, Eddington ND, Fasano A: Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006;58:15-28.
21. Antalis TM, Shea-Donohue T, Vogel SN, Sears C, Fasano A: Mechanisms of disease: protease functions in intestinal mucosal pathobiology. Nat Clin Pract Gastroenterol Hepatol 2007;4:393-402. (Pubitemid 47307607)
22. Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, Thakar M, Iacono G, Carroccio A, D'Agate C, Not T, Zampini L, Catassi C, Fasano A: Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-419. (Pubitemid 43675406)
23. Marinaro M, Di Tommaso A, Uzzau S, Fasano A, De Magistris MT: Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect Immun 1999;67:1287-1291. (Pubitemid 29108506)
24. Marinaro M, Fasano A, De Magistis M: Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect Immun 2003;71:1897-1902. (Pubitemid 36368721)
25. Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, Goldblum SE: Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000;355:1518-1519. (Pubitemid 30237361)
26. Wang W, Uzzau S, Goldblum SE, Fasano A: Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000;113:4435-4440. (Pubitemid 32117904)
27. Fasano A, Uzzau S, Fiore C, Margaretten K: The enterotoxic effect on zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 1997;112:839-846. (Pubitemid 27113809)
28. Clemente M, De Virgiliis S, Kang JS, Macatagney R, Musu MP, Di Pierro MR, Drago S, Congia M, Fasano A: Early effect of gliadin on enterocyte intracellular signaling in intestinal barrier function. Gut 2003;52:218-223. (Pubitemid 36115062)
29. Turner JR, Rill BK, Carlson SL, Carnes D, Kerner R, Mrsny RJ, Madara JL: Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 1997;273:C1378-C1385.
30. Atisook K, Carlson S, Madara JL: Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia. Am J Physiol 1990;258:C77-C85. (Pubitemid 20053598)
31. Wei J, Hemmings GP: Gene, gut and schizophrenia: the meeting point for the gene-environment interaction in developing schizophrenia. Med Hypotheses 2005;64:547-552. (Pubitemid 40023017)
32. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R: Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006;49:2824-2827. (Pubitemid 44730283)
33. Cordain L, Toohey L, Smith MJ, Hickey MS: Modulation of immune function by dietary lectins in rheumatoid arthritis. Br J Nutr 2000;83:207-217. (Pubitemid 30125215)
34. Bruewer M, Samarin S, Nusrat A: Inflammatory bowel disease and the apical junctional complex. Ann NY Acad Sci 2006;1072:242-252. (Pubitemid 44448457)
35. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC: Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-1294. (Pubitemid 43829995)
36. Porras M, Martín MT, Yang PC, Jury J, Perdue MH, Vergara P: Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis 2006;12:843-852. (Pubitemid 44352711)
37. D'Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, Vettorato MG, Sturniolo GC: Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 2006;23:1455-1461.
38. Barbara G: Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am J Gastroenterol 2006;101:1295-1298. (Pubitemid 43829996)
39. Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, Franke L, van't Slot R, van Belzen MJ, Lavrijsen IC, Diosdado B, Daly MJ, Mulder CJ, Mearin ML, Meijer JW, Meijer GA, van Oort E, Wapenaar MC, Koeleman BP, Wijmenga C: Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 2005;37:1341-1344. (Pubitemid 41722189)
40. Pizzuti D, Bortolami M, Mazzon E, Buda A, Guariso G, D'Odorico A, Chiarelli S, D'Incà R, De Lazzari F, Martines D: Transcriptional downregulation of tight junction protein ZO-1 in active coeliac disease is reversed after a gluten-free diet. Dig Liver Dis 2004;36:337-341. (Pubitemid 41115464)
41. Di Cagno R, De Angelis M, Auricchio S, Greco L, Clarke C, De Vincenzi M, Giovannini C, D'Archivio M, Landolfo F, Parrilli G, Minervini F, Arendt E, Gobbetti M: Sourdough bread made from wheat and non-toxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004;70:1088-1096. (Pubitemid 38568235)
42. Smecuol E, Bai JC, Vazquez H, Kogan Z, Cabanne A, Niveloni S, Pedreira S, Boerr L, Mauriño E, Meddings JB: Gastrointestinal permeability in celiac disease. Gastroenterology 1997;112:1129-1136. (Pubitemid 27157523)
43. Hollander D: Crohn's diseasea permeability disorder of the tight junction? Gut 1988;29:1621-1624.
44. Ukabam SO, Clamp JR, Cooper BT: Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983;27:70-74. (Pubitemid 13041629)
45. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H: Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-1439. (Pubitemid 23161445)
46. D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC: Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999;94:2956-2960. (Pubitemid 29482764)
47. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR: Interferongamma and tumor necrosis factoralpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409-419. (Pubitemid 40189038)
48. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, Turner JR: A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002;123:163-172. (Pubitemid 34747537)
49. Ma TY, Boivin MA, Ye D, Pedram A, Said HM: Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288:G422-G430. (Pubitemid 40261739)
50. Graham WV, Wang F, Clayburgh DR, Cheng JX, Yoon B, Wang Y, Lin A, Turner JR: Tumor necrosis factorinduced long myosin light chain kinase transcription is regulated by differentiationdependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem 2006;281:26205- 26215. (Pubitemid 44401828)
51. Ciclitira PJ, Johnson MW, Dewar DH, Ellis HJ: The pathogenesis of coeliac disease. Mol Aspects Med 2005;26:421-458. (Pubitemid 41728297)
52. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Auricchio S, Picard J, Osman M, Quaratino S, Londei M: Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-37. (Pubitemid 36835817)
53. Gianfrani C, Auricchio S, Troncone R: Adaptive and innate immune responses in celiac disease. Immunol Lett 2005;99:141-145. (Pubitemid 40966029)
54. Thomas KE, Sapone A, Fasano A, Vogel SN: Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in celiac disease. J Immunol 2006;176:2512-2521. (Pubitemid 43201702)
55. Ventura A, Magazzu G, Greco L: Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for auto immune disorders in celiac disease. Gastroenterology 1999;117:297-303. (Pubitemid 29352936)
56. Schuppan D: Current concepts of celiac disease pathogenesis. Gastroenterology 2000;119:234-242. (Pubitemid 30452598)
57. National Institutes of Health Consensus Development on Celiac Disease. Consensus Development Conference, Bethesda, 2004.
58. Feld JJ, Meddings J, Heathcote EJ: Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci 2006;51:1607-1613. (Pubitemid 44379304)
59. Funda DP, Kaas A, Bock T, Tlaskalová-Hogenová H, Buschard K: Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 1999;15:323-327. (Pubitemid 29535091)
60. Meddings JB, Jarand J, Urbanski SJ, Hardin J, Gall DG: Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 1999;276:G951-G957. (Pubitemid 29214109)
61. Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R, Fasano A: Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci USA 2005;102:2916-2921. (Pubitemid 40299891)
62. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, Rewers M: Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003;290:1713-1720. (Pubitemid 37430621)
63. Clayburgh DR, Barrett TA, Tang Y, Meddings JB, Van Eldik LJ, Watterson DM, Clarke LL, Mrsny RJ, Turner JR: Epithelial myosin light chain kinasedependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 2005;115:2702-2715. (Pubitemid 41434398)
64. Blair SA, Kane SV, Clayburgh DR, Turner JR: Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 2006;86:191-201. (Pubitemid 43117598)
65. Karyekar CS, Fasano A, Raje S, Lu R, Dowling TC, Eddington ND: Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J Pharm Sci 2003;92:414-423. (Pubitemid 36169314)